(Reuters) – Chinese language biotech corporations WuXi AppTec and WuXi Biologics (HK:), that are being focused by a forthcoming U.S. nationwide safety laws, are engaged on gross sales of a few of their operations, the Monetary Occasions reported on Thursday, citing folks accustomed to the matter.
WuXi AppTec has put its cell and gene remedy manufacturing arm WuXi Superior Therapies, which operates 4 laboratories and manufacturing services in Philadelphia, up on the market, the newspaper reported.
WuXi Biologics can also be working with advisers to check curiosity in a few of its European manufacturing services, FT reported, citing three folks accustomed to the state of affairs.
